Trial Profile
A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms CheckMate-004
- Sponsors Bristol-Myers Squibb
- 10 Mar 2020 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results assessing Overall Survival after 5 years of overall study follow-up and assess survival rates after stopping treatment, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2019 Results of 5-year analysis, presented in a Bristol-Myers Squibb media release.